Reanalyzing data from 15 clinical trials, the researchers show that independent action — in which drugs do not enhance each other’s effectiveness–can accurately explain gains in survival for most combination cancer therapies when compared to single-drug treatments. Read more . . .
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of “bet hedging,” according to a new study published by Harvard Medical School researchers in Cell on Dec. 14.